CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
Vitamin D +1 moredrug
Likely dose
Vitamin D 4000 IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01093417
NCT01093417Phase 2Completed
CompareCT.gov

The Effect of Vitamin D Supplementation on Endothelial Function, Inflammation and Insulin Resistance in HIV

University Hospitals Cleveland Medical Center·interventional·Posted Mar 25, 2010·Updated Jul 14, 2016

In Brief

A Phase 2 clinical trial evaluating Vitamin D and Placebo for Human Immunodeficiency Virus (HIV) and 2 related conditions. Completed, enrolled 45 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate how Vitamin D affects endothelial function, inflammation, lipids, insulin resistance, vitamin D levels, and parathyroid hormone (PTH).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus (HIV), Vitamin D Deficiency, HIV Infections
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 25, 2010
Enrollment StartJan 1, 2010
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 16.3 years ago

Interventions

Vitamin Ddrug

Vitamin D 4000 IU will be administered to enrollees on the active comparator arm

Placeboother

Placebo pills will be administered to enrollees in this arm